Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

AVITA Medical Inc

Healthcare US AVHHL

0.845USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.730.73
LowHigh

52 Week Range

0.562.28
LowHigh

Fundamentals

  • Previous Close 0.84
  • Market Cap126.60M
  • Volume150
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-40.24000M
  • Revenue TTM71.61M
  • Revenue Per Share TTM2.57
  • Gross Profit TTM 58.82M
  • Diluted EPS TTM-0.35

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Income before tax -48.57600M -61.79100M -35.31500M -26.62900M -39.11534M
Minority interest - - - - -
Net income -48.58700M -61.84500M -35.38100M -26.66500M -39.16822M
Selling general administrative 27.37M 33.20M 65.62M 23.33M 34.27M
Selling and marketing expenses 52.54M 58.20M - 21.91M 32.19M
Gross profit 58.82M 55.16M 42.36M 28.38M 41.69M
Reconciled depreciation 2.35M 1.13M 0.63M 0.57M 0.57M
Ebit -41.93400M -56.43000M - -27.50500M -41.02776M
Ebitda -39.58700M -55.30400M - -26.04500M -39.56776M
Depreciation and amortization 2.35M 1.13M - 1.46M 1.46M
Non operating income net other - - - - -
Operating income -41.93400M -56.59300M -42.65500M -27.50500M -40.40209M
Other operating expenses 113.54M 120.84M - 61.93M 89.65M
Interest expense 5.00M 5.36M 1.14M 0.02M 0.02M
Tax provision 0.01M 0.05M 0.07M 0.04M 0.04M
Interest income - - - - -
Net interest income -5.00400M -5.36100M -1.14300M -0.01600M -0.01600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.01M 0.05M - 0.04M 0.05M
Total revenue 71.61M 64.25M 50.14M 34.42M 50.56M
Total operating expenses 100.75M 111.75M 92.80M 55.88M 80.78M
Cost of revenue 12.79M 9.09M 7.78M 6.04M 8.87M
Total other income expense net -6.64200M -5.19800M 8.48M 0.88M 1.29M
Discontinued operations - - - - -
Net income from continuing ops -48.58700M -61.84500M -35.38100M -26.66500M -26.66500M
Net income applicable to common shares - - - -26.66500M -26.66500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 56.39M 79.71M 111.64M 98.26M 144.34M
Intangible assets 5.64M 5.57M 0.49M 0.47M 0.68M
Earning assets - - - - -
Other current assets 1.29M 1.88M - 1.03M 3.61M
Total liab 73.04M 75.21M 62.58M 13.52M 19.87M
Total stockholder equity -16.65000M 4.50M 49.06M 84.74M 124.47M
Deferred long term liab - - - - -
Other current liab 62.68M 12.96M 0.34M 6.88M 6.89M
Common stock -1.29000M 0.00300M - 0.00300M 0.00441M
Capital stock 0.00300M 0.00300M 0.00300M 0.00300M 0.00300M
Retained earnings -408.40100M -359.81400M -297.96900M -262.58800M -385.71551M
Other liab - - - 2.52M 2.52M
Good will - - - - -
Other assets - - - 1.36M 0.00000M
Cash 10.24M 14.05M 22.12M 18.16M 26.68M
Cash and equivalents - - - - -
Total current liabilities 62.68M 20.16M 13.20M 10.69M 15.71M
Current deferred revenue - - - 0.19M 0.19M
Net debt -8.10800M 31.93M 17.69M -17.24600M -26.23162M
Short term debt - 0.90M - 0.61M 0.61M
Short long term debt 42.98M - - - -
Short long term debt total 2.13M 45.98M - 0.92M 0.45M
Other stockholder equity 394.41M 366.25M - 339.70M 499.17M
Property plant equipment - - - 2.05M 2.05M
Total current assets 35.49M 57.00M 104.01M 87.46M 128.47M
Long term investments - - 0.00000M 6.93M 6.93M
Net tangible assets - - - 84.28M 84.28M
Short term investments 7.94M 21.84M 66.94M 61.18M 89.86M
Net receivables 9.09M 11.96M 7.66M 4.96M 5.19M
Long term debt - 42.24M 39.81M - -
Inventory 6.93M 7.27M 5.60M 2.12M 3.12M
Accounts payable 8.96M 6.29M 3.79M 3.00M 4.41M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.36700M -1.93900M - 7.63M 11.02M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.73M 3.55M 2.53M 1.36M 2.00M
Deferred long term asset charges - - - - -
Non current assets total 20.90M 22.71M 7.63M 10.81M 15.87M
Capital lease obligations 3.06M 3.74M 2.60M 0.92M 0.92M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Investments 14.19M 37.36M 1.61M -19.33200M -19.33200M
Change to liabilities - - - 0.03M 0.03M
Total cashflows from investing activities 12.45M 37.36M - -19.33200M -19.33200M
Net borrowings - 0.00000M - - -
Total cash from financing activities 14.94M 3.51M 40.37M 0.90M 1.32M
Change to operating activities - - - -0.45800M -0.45800M
Net income -48.58700M -61.84500M -35.38100M -26.66500M -39.16822M
Change in cash -3.80700M -8.06800M 3.95M -37.54800M -121.27782M
Begin period cash flow 14.05M 22.12M 18.16M 55.71M 147.96M
End period cash flow 10.24M 14.05M 22.12M 18.16M 26.68M
Total cash from operating activities -31.19500M -48.93900M -38.01100M -19.09000M -28.04130M
Issuance of capital stock 14.79M 0.00000M - 0.00000M 0.00000M
Depreciation 2.04M 1.13M 0.63M 0.57M 0.83M
Other cashflows from investing activities -1.73900M -0.16200M - - -
Dividends paid - - - - -
Change to inventory 0.81M -2.16000M -3.69300M -0.37100M -0.54496M
Change to account receivables 3.63M -4.17100M -4.17200M -0.39500M -0.58022M
Sale purchase of stock - - - - -
Other cashflows from financing activities 14.94M 3.51M - 0.90M 1.32M
Change to netincome - - - 7.87M 7.87M
Capital expenditures 1.74M 9.33M 1.45M 0.53M 0.66M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 3.44M -4.67800M -6.57400M -1.19600M -1.79793M
Stock based compensation 9.52M 13.50M 8.38M 7.00M 10.28M
Other non cash items 5.83M 2.96M 4.61M 1.21M 1.81M
Free cash flow -31.19500M -58.27200M -39.45800M -19.61500M -28.70524M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVHHL
AVITA Medical Inc		 - -% 0.84 - 11.81 1.77 11.03 2.43 -6.1664
ABT
Abbott Laboratories		 0.02 0.02% 86.99 25.97 17.24 3.57 3.20 3.81 16.75
SYK
Stryker Corporation		 1.70 0.58% 295.00 44.07 24.94 5.51 6.12 6.05 25.73
MDT
Medtronic PLC		 4.20 5.69% 77.95 26.60 15.87 3.35 2.08 3.90 14.12
BSX
Boston Scientific Corp		 0.01 0.02% 47.69 31.49 17.24 4.41 3.65 4.88 19.19

Reports Covered

Stock Research & News

View All

Profile

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.

AVITA Medical Inc

28159 Avenue Stanford, Valencia, CA, United States, 91355

Key Executives

Name Title Year Born
Mr. James M. Corbett CEO, Pres & Exec. Director 1958
Mr. Michael Bria Holder MBA Chief Financial Officer 1963
Ms. Kathy M. McGee Chief Operating Officer 1966
Mr. Andrew Quick Chief Technology Officer 1971
Ms. Donna Shiroma Gen. Counsel & Sec. 1962
Ms. Erin Liberto Chief Commercial Officer 1975
Mr. David Fencil VP of Global Operations NA
Ms. Debbie Garner VP of Global Marketing NA
Mr. James M. Corbett CEO, President & Executive Director 1958
Mr. David O'Toole Chief Financial Officer 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.